Science & Technology A Novel Potential Treatment for Parkinson’s Disease Spheramine GLYPH<H23006> Spheramine GLYPH<H23006> , Titan’s novel cell therapy for Parkinson’s disease, uses Titan’s innovative CCM GLYPH<H23008>  tech- nology that can potentially overcome the limitations of other cell-based approaches. Spheramine consists of human retinal pigment epithelial (RPE) cells attached to microcarriers. RPE cells, normally found in the eye, act to provide enhanced levels of dopamine, the neurotransmitter deficient in Parkinson’s disease. Microcarriers enhance the ability of the cells to survive in the brain and may also protect cells from rejection. Titan recently completed a pilot clinical study of Spheramine in patients with late-stage Parkinson’s disease, in which Spheramine demonstrated an average of nearly 50 percent improvement in motor function twelve months after treatment. Spheramine is being developed by Titan in collaboration with Schering AG. Four Spheramine is  injected into  the regions of  the brain in need of dopamine Spheramine RPE cells Microcarriers Indication(s) Preclinical Phase 1 Phase 2 Phase 3 Parkinson's Disease Spher amine® Average Improvement in Phase I/II Study in Late–Stage Parkinson’s Disease  (Months Post Treatment) 0 10 20 30 40 50 1 3 6 9 12 (% Improvement in UPDRS Motor Score “Off” Medication)